MHRA GLP-1 supply update: what changed in 2026
The MHRA's Drug Safety Update programme has published multiple notices since 2023 covering supply constraints on Ozempic, Wegovy, Mounjaro, and Saxenda. The core message has not changed: prescribers are asked to prioritise licensed use, and off-label prescribing for cosmetic weight loss remains discouraged.
Nothing in the MHRA guidance changes the legal status of unlicensed research peptides. Research-grade semaglutide, tirzepatide, and retatrutide sold for in-vitro study fall outside the MHRA licensing regime entirely — they are not medicines and cannot be sold, supplied, or administered as such.
Our GLP-1 brand names map lists every currently licensed UK product alongside its underlying compound.
More in Regulatory & MHRA
Referenced supplier: PeptidesUK4U
Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
- HPLC-tested batches
- Batch-level CoAs
- UK cold-chain despatch
- 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
- 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
- 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.